Choroidal melanoma drug preserved vision in Phase II study
Drug Discovery World
FEBRUARY 17, 2023
Aura Biosciences has announced positive interim Phase II safety and efficacy data for belzupacap sarotalocan (bel-sar) as a first-line treatment for patients with early-stage choroidal melanoma with suprachoroidal administration. The results showed a statistically significant reduction in tumour growth rate compared to each patient’s documented growth rate at study entry, and a 100% tumour control rate.
Let's personalize your content